BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
Single-arm, open label study to determine the 18 week progression-free survival rate of the
combination of BXCL701 and pembrolizumab in patients with pancreatic ductal adenocarcinoma in
the second-line metastatic setting.